J. C. Goin, Centro de Estudios Farmacológicos y Botánicos, Facultad de Medicina (UBA), Paraguay 2155, P.16 (C1121ABG) Buenos Aires, Argentina. E-mail: email@example.com
Circulating immunoglobulin (Ig)G antibodies against M2 muscarinic acetylcholine receptors (M2 mAChR) have been implicated in Chagas' disease (ChD) pathophysiology. These antibodies bind to and activate their target receptor, displaying agonist-like activity through an unclear mechanism. This study tested the ability of serum anti-M2 mAChR antibodies from chronic ChD patients to modulate M2 muscarinic receptor–receptor interaction by bioluminescence resonance energy transfer (BRET). Human embryonic kidney (HEK) 293 cells co-expressing fusion proteins M2 mAChR-Renilla luciferase (RLuc) and M2 mAChR-yellow fluorescent protein (YFP) were exposed to the serum IgG fraction from ChD patients, and BRET between RLuc and YFP was assessed by luminometry. Unlike serum IgG from healthy subjects and conventional muscarinic ligands, ChD IgG promoted a time- and concentration-dependent increase in the BRET signal. This effect neither required cellular integrity nor occurred as a consequence of receptor activation. Enhancement of M2 receptor–receptor interaction by ChD IgG was receptor subtype-specific and mediated by the recognition of the second extracellular loop of the M2 mAChR. The monovalent Fab fragment derived from ChD IgG was unable to reproduce the effect of the native immunoglobulin. However, addition of ChD Fab in the presence of anti-human Fab IgG restored BRET-enhancing activity. These data suggest that the modulatory effect of ChD IgG on M2 receptor–receptor interaction results from receptor cross-linking by bivalent antibodies.
Circulating immunoglobulin (Ig) G antibodies against M2 muscarinic acetylcholine receptors (M2 mAChR) have been implicated in Chagas' disease (ChD) pathophysiology [1–5]. These antibodies are highly prevalent in chronic ChD patients with sinus node dysfunction , achalasia  and megacolon . Because there is a strong association between anti-M2 mAChR antibodies and dysautonomia [1,2], these antibodies have been proposed as a marker for cardiac autonomic dysfunction in chronic ChD patients . Serum anti-M2 mAChR antibodies with clinical significance have also been described in patients suffering from idiopathic dilated cardiomyopathy  and hypertrophic cardiomyopathy .
Although the precise mechanism of action of ChD anti-M2 mAChR antibodies is still unclear, previous reports agree that these antibodies recognize the second extracellular loop (II-ECL) of M2 mAChR [2,9], and subsequently activate their target receptor, displaying agonist-like activity [1,10,11]. In fact, anti-M2 mAChR antibodies decrease cyclic adenosine-5′-monophosphate (cAMP) accumulation [10,11], enhance cyclic guanosine monophosphate (cGMP) production [10,11] and inhibit L-type Ca2+ currents . As a result, they elicit negative inotropic and chronotropic effects in the rodent myocardium [1–3,6,9,10] and increase tonic contraction of rat oesophageal and colonic smooth muscle [4,5], mimicking the effects of muscarinic partial agonists. Radioligand binding studies have shown that these antibodies also inhibit the specific binding of classical muscarinic antagonists to the M2 receptor in cardiac and gastrointestinal smooth muscle membrane preparations [1,5,10–13]. Because the serum IgG fraction from ChD patients can increase the efficacy and affinity of agonists and decrease the affinity of antagonists on cardiac muscarinic receptors, anti-M2 mAChR antibodies are also believed to act as muscarinic allosteric modulators .
Classical pharmacological and biochemical studies as well as modern biophysical approaches based on bioluminescence or fluorescence resonance energy transfer [e.g. bioluminescence resonance energy transfer (BRET) or fluorescence resonance energy transfer (FRET)] have provided evidence to support that mAChR form constitutive dimers or higher-order oligomers [14–19]. In particular, the M2 receptor subtype has been shown to form homotropic complexes (dimers or tetramers) [17,19] and heterodimers with either other mAChR subtypes [15,17] or non-muscarinic G-protein coupled receptors . Receptor–receptor interactions involving M2 mAChR have been implicated in essential aspects of receptor pharmacology, such as ligand binding , signalling , long-term regulation  and trafficking .
Given the pharmacological relevance of muscarinic receptor oligomerization and the ability of serum antibodies from ChD patients to bind to and activate M2 mAChR, we assessed whether these anti-autonomic receptor antibodies would modulate M2 muscarinic receptor–receptor interactions. The present study shows that circulating IgG antibodies against M2 mAChR from chronic ChD patients enhance M2 mAChR receptor–receptor interaction by receptor cross-linking. In addition, it analyses the specificity of antibody–receptor interaction at the molecular level, and discusses the implications of these findings in ChD pathophysiology.
Materials and methods
Serum samples were obtained from 15 patients with chronic ChD and 15 control healthy subjects recruited at the D. F. Santojanni Hospital, Buenos Aires, Argentina. Diagnosis of ChD was made on the basis of three standard serological reactions against Trypanosoma cruzi: indirect haemagglutination, indirect immunofluorescence and enzyme linked-immunosorbent assay (ELISA). ChD patients showed signs and symptoms of chronic heart disease – with or without congestive heart failure – and autonomic nervous system dysfunction (dysautonomia), as shown by abnormal responses to two or more of the following diagnostic tests: Valsalva manoeuvre, tilting, hyperventilation and coughing tests [1,2]. Control subjects exhibited negative serology for T. cruzi infection and normal tests for dysautonomia. All methodologies used in this study conformed to the standards set by the Declaration of Helsinki. Every ChD patient or healthy subject gave fully informed consent under a protocol approved by the Santojanni Hospital's Ethics Committee. The presence of anti-M2 mAChR in ChD patients was detected using the immunoenzymatic protocol described below. Although all ChD sera tested positive, only those yielding optical density readings at 405 nm (OD405nm) between 1·0 and 1·5 were selected for IgG purification and further studies.
Purification of serum IgG and Fab fragments
Serum IgG fractions from selected ChD patients and control subjects were purified by diethylaminoethyl (DEAE) cellulose chromatography, as described previously . Fab fragments from ChD or control IgG were prepared using immobilized papain (Pierce, Thermo Fisher Scientific, Rockford, IL, USA) followed by chromatography through protein G-agarose (Roche Diagnostics, Indianapolis, IN, USA) to remove undigested IgG and Fc fragments. Protein concentration of IgG and Fab samples were determined by Lowry's method .
Purification of monospecific anti-M2 mAChR antibodies
ChD IgG fractions were subjected to affinity chromatography against a synthesized 25-mer-peptide (pM2: VRTVEDGECYIQFFSNAAVTFGTAI), corresponding to the amino acid sequence of the II-ECL of human M2 mAChR (residues 169–193) as described previously . The non-anti-pM2 fraction was first eluted with PBS and specific anti-pM2 antibodies were then eluted with 3 m KSCN, 1 m NaCl. Both IgG fractions were dialysed against phosphate-buffered saline (PBS) and concentrated by ultrafiltration. Immune reactivities of non-anti-peptide and monospecific anti-pM2 IgG fractions were monitored by ELISA.
The pM2 peptide was coated onto microtitre plates (2·5 µg/well) in 0·1 M Na2CO3 buffer pH 11, for 18 h at 4°C. The wells were then saturated with 10% v/v fetal bovine serum (FBS) in PBS (FBS/PBS) for 2 h at 37°C. One hundred microlitres of dilutions of patient sera (1:50) or purified IgG fractions in PBS/bovine serum albumin (BSA) 1% were allowed to react with the peptide for 2 h at 37°C. After the wells were washed three times with 0·05% Tween-20 in PBS, 100 µl of alkaline phosphatase-conjugated goat anti-human IgG (Jackson ImmunoResearch, West Grove, PA, USA) diluted 1:6000 in PBS/BSA 1% was added to each well and allowed to bind for 1 h at 37°C. OD405nm was measured after the incubation with 1 mg/ml p-nitrophenyl phosphate for 30 min at room temperature. Sera with OD values higher than the mean + 3 standard deviations (s.d.) of control sera were taken as positive for anti-pM2 antibodies. The presence of anti-pM2 antibodies in ChD IgG fractions after affinity chromatography was confirmed by performing ELISA inhibition tests. These experiments were carried out by pre-incubating various amounts of anti-pM2 IgG or non-anti-pM2 IgG fractions in the presence or absence of soluble peptide (pM2) for 60 min at 37°C, before incubating either IgG fraction with the immobilized peptide.
Plasmids, cell culture and transfection
M2 and M3 mAChR-RLuc and mAChR-YFP fusion protein constructs were generated by ligating humanized Renilla luciferase (RLuc) or enhanced yellow fluorescence protein (YFP) moieties to the C-terminal end of the respective receptors. Details regarding the construction procedures as well as the pharmacological characterization of all fusion proteins have been described in a previous study . Human embryonic kidney (HEK) 293 cells were grown in Dulbecco's modified Eagle's medium (Applichem GmbH, Darmstadt, Germany) supplemented with 10% FBS, penicillin (100 units/ml) and streptomycin sulphate (0·1 mg/ml) at 37°C in a humidified 5% CO2 environment. Transient transfections were performed on 70–80% confluent cells using a calcium phosphate precipitation protocol .
BRET assays on cells
To monitor receptor–receptor interactions in living cells, BRET assays were performed on cells co-expressing M2-RLuc (or M3-RLuc) and M2-YFP (or M3-YFP) at equimolar amounts. Expression levels of donor and acceptor fusion proteins were determined, respectively, by measuring luminescence and fluorescence in each BRET experiment and correlating those values with the amount of mAChR-binding sites in the same cells, as described previously  (data not shown). Thirty-six h after transfection, cells were washed with warm PBS and resuspended in modified Krebs–Ringer–HEPES buffer (104 mm NaCl, 5 mm KCl, 1·2 mm MgSO4, 1·2 mm CaCl2, 1·2 mm Na2HPO4, 10 mm glucose, 20 mm HEPES, pH 7·4) supplemented with 0·1% BSA (KRHA) . Transfected cells were then placed in 1·5 ml-clear microcentrifuge tubes at a density of 100 000 cells/tube, and treated with different concentrations of muscarinic ligands or antibodies (IgGs or Fab fragments) at room temperature for the desired time, from 15 to 60 min. Coelenterazine h (Promega, Madison, WI, USA) was added at a final concentration of 5 µm, and readings were collected 15 min later in a Turner 20/20 luminometer (Turner Designs, Sunnyvale, CA, USA), which allowed the sequential integration of the emission signals to be detected in the 510–590 nm and 440–500 nm windows by using filters with the appropriate band pass . The BRET signal was defined as the ratio of the light intensity measured at 510–590 nm over 440–500 nm. BRET signal values were transformed into BRET ratio values by subtracting the background signal detected when the receptor-RLuc constructs were expressed alone. Consequently, the BRET ratio was defined as [(emission at 510–590 nm) − (emission at 440–500 nm) × Cf]/(emission at 440–500 nm), where Cf refers to (emission at 510–590 nm)/(emission at 440–500 nm) for the corresponding mAChR-RLuc expressed alone . Because the BRET ratio may vary according to the presence of IgG fractions (or their Fab fragments) from different species, the effects of human IgGs or Fabs were normalized by that of a standard IgG (normal goat IgG) (or its Fab fragment), at the same concentration. Goat IgG was chosen because its effect on BRET was similar to the average effect of human IgG from control subjects. Consequently, net changes in BRET ratio values obtained following treatment with muscarinic ligands, human IgGs or their Fab fragments, were expressed as ΔBRET = (BRET ratio after treatment with muscarinic ligands, human IgGs or Fab fragments)–(BRET ratio after treatment with buffer alone, goat IgG or Fab from goat IgG, respectively). This correction also allowed us to compare ΔBRET values from different experiments. All BRET ratio and ΔBRET values were multiplied by 1000 and expressed as milibrets (mB).
BRET assays on membranes
Membranes were prepared from cells expressing M2-RLuc alone or co-expressing M2-RLuc and M2-YFP at equimolar numbers using the transfection protocol described above. Transfected cells were washed twice with warm PBS and then glass–glass homogenized ×20 in ice-cold buffer containing 50 mm Na/KPO4, pH 7·4, 1 mm ethylenediamine tetraacetic acid (EDTA) and a protease inhibitor cocktail . Homogenates were centrifuged at 1000 g for 5 min at 4°C to remove nuclei and unbroken cells. The supernatant was then centrifuged at 10 000 g for 20 min, and the pellet was washed twice in the same buffer. Membrane preparations were stored at −80°C until used. For BRET assays, membranes were diluted 1:10 with KRHA buffer or 5 mm Na/KPO4, pH 7·4 supplemented with BSA 0·1%. The remaining part of the procedure was the same as that used for cells.
Data were analysed using Prism 5 software (GraphPad, La Jolla, CA, USA). One- or two-way analyses of variance followed by Bonferroni post-hoc tests were used as required. Results were expressed as means ± standard error of the mean (s.e.m.). Differences between means were considered significant if P < 0·05.
Effect of ChD IgG on BRET in cells and membranes
HEK 293 cells were co-transfected with M2-RLuc and M2-YFP at a 1:3 DNA ratio, which allowed equimolar expression of both fusion proteins, according to a previous study . Under these conditions the total amount of expressed M2 mAChR binding sites ranged from 140 to 350 fmol/mg cell protein, as determined by a [3H]-quinuclidinyl benzilate (QNB) binding assay. These values are consistent with physiological levels of receptor expression . Addition of RLuc substrate coelenterazine h to co-transfected cells generated a basal BRET ratio of 50–65 mB. Quantitative analysis of receptor–receptor interaction has demonstrated that this basal BRET value is not a consequence of receptor construct over-expression but the result of constitutive M2 receptor–receptor interaction .
Treatment of co-transfected cells with ChD IgGs promoted a time- and concentration-dependent increase in the BRET ratio, while control IgGs induced a negligible effect which did not change over time (Fig. 1a,b). Because we noticed that ChD IgG (10 µm) was ineffective, we investigated the influence of total IgG concentration on the BRET signal. We exposed our M2-RLuc/M2-YFP BRET cell system to various concentrations of ChD IgG in the presence of additional amounts of control IgG, keeping a total IgG concentration of 50 µm. Under these conditions, ChD IgG (10 µm) led to a significant increase in the BRET ratio, suggesting that the presence of a carrier immunoglobulin fraction increases the specific interaction of BRET-enhancing antibodies with the M2 mAChR BRET pair (Fig. 1b).
With regard to the specificity of the carrier protein in our BRET assay, we compared the carrier effect of control IgG with that of goat IgG or BSA. Briefly, treatment of our cellular M2-RLuc/M2-YFP BRET system with 10 µm ChD IgG supplemented with 40 µm goat IgG led to a significant increase in BRET, compared with 10 µm control IgG supplemented with 40 µm goat IgG or 10 µm ChD IgG alone (Supplementary Table S1). Under identical experimental conditions, the addition of supplementary amounts of BSA could not enhance the effect of 10 µm ChD IgG on BRET. These results indicate that goat IgG, but not BSA, is capable of mimicking the carrier effect of control IgG. Although these findings would suggest that the carrier effect is specific of IgG, other proteins with various physicochemical properties should be tested in order to define the specificity of the carrier protein.
Treatment of membranes from cells co-expressing M2-RLuc and M2-YFP with ChD IgG resulted in a similar concentration-dependent increase in the BRET signal, indicating that energy transfer between these fusion proteins does not require cellular integrity, and occurs at the cellular membrane level (Fig. 1c). The effect of 10 µm ChD IgG on BRET appears to be higher than that promoted by control IgG at the same concentration; however, both ΔBRET values are not statistically different (P > 0·05). Therefore, we should not rule out the need of a carrier protein to obtain significant differences between ChD and control BRET values in membranes at low IgG concentrations.
ChD IgG was unable to modify basal BRET signals in cells expressing alternative BRET pairs, such as M3-RLuc/M3-YFP, M2-RLuc/M3-YFP or M3-RLuc/M2-YFP. Resulting BRET values were similar to those obtained in cells treated with IgG from control subjects (Fig. 2). These data suggest that the effect of ChD IgG on muscarinic receptor–receptor interaction results from the specific recognition of the M2 muscarinic receptor subtype.
Effects of conventional muscarinic ligands
The effect of ChD IgG on M2 muscarinic receptor–receptor interaction was compared to that of conventional muscarinic ligands. Unlike ChD IgG, a full agonist (carbachol), a partial agonist (pilocarpine), an antagonist (atropine) and an allosteric modulator (gallamine) were unable to enhance the BRET signal in the cellular M2-RLuc/M2-YFP expression system, compared with buffer alone (KRHA) (Fig. 3). Moreover, a tendency for slightly decreased BRET values in the presence of all muscarinic ligands tested was observed, especially at the highest ligand concentrations. Slight variations in energy transfer promoted by 10 µm carbachol could not be antagonized by 10 µm atropine (Supplementary Fig. S1), suggesting that they do not result from receptor activation or any other event downstream. Rather, they seem to reflect negligible changes in constitutive M2 receptor–receptor interaction, in agreement with our previous report .
Involvement of the II-ECL of the M2 mAChR
Affinity chromatography of the whole IgG from ChD patients against an immobilized peptide corresponding in sequence with the II-ECL of human M2 receptor (pM2) resulted in the isolation of two antibody fractions: non-anti-pM2 IgG, eluted with PBS, and anti-pM2 IgG, eluted with 3 m KSCN, 1 m NaCl. Immune reactivity against pM2 was tested on both fractions by ELISA inhibition tests, which confirmed the efficacy of the chromatographic procedure (Supplementary Fig. S2).
In terms of reactivity against pM2, preliminary ELISA data had demonstrated that a 1–2 µm concentration of anti-pM2 ChD IgG was equivalent to a 50 µm concentration of the total serum IgG fraction for a given ChD patient (data not shown). Therefore, we tested the BRET activity of anti-pM2 fractions IgG (2 µm) from various ChD patients. For the purpose of the BRET assay, these fractions were supplemented with either control or non-anti-pM2 IgG fractions as carrier immunoglobulins, keeping a total IgG concentration of 50 µm, according to the data discussed above (Fig. 1b). Under these conditions, the anti-pM2 ChD IgG fraction promoted a significant increase in the BRET signal (Fig. 4a). As expected, the effect of 50 µm non-anti-pM2 ChD IgG alone was similar to that of control IgG at the same concentration. These results were confirmed by performing concentration–response curves of anti-pM2 ChD IgG supplemented with non-anti-pM2 ChD or control IgG, as indicated above. As shown in Fig. 4b, monospecific anti-pM2 antibodies promoted maximal increases in energy transfer of 16·0 ± 4·2 and 14·1 ± 3·8 mB, respectively, which were similar to the BRET ratio induced by 50 µm total ChD IgG (13·0 ± 1·32 mB) (Fig. 4a).
Because both anti-M2 mAChR antibodies and muscarinic allosteric ligands had been shown to interact to the acidic amino acid cluster (EDGE) at the II-ECL of M2 receptor , we investigated whether a muscarinic allosteric modulator could modulate the BRET-enhancing activity of ChD anti-M2 mAChR antibodies. Membranes from cells expressing the M2Rluc/M2-YFP BRET pair were incubated with 50 µm control IgG or ChD IgG in the presence or absence of 100 µm gallamine (allosteric ligand) or 10 µm atropine (orthosteric ligand) for 60 min at room temperature. These treatments were carried out in the presence of low ionic strength buffer conditions (5 mm Na/KPO4, BSA 0·1%, pH 7·4), which favour allosteric interactions . Under these conditions, gallamine – but not atropine – inhibited the stimulatory effect of ChD IgG on BRET, whereas neither ligand was able to modify BRET values from membranes treated with buffer alone or control IgG (Fig. 5).
Together, these data indicate that the effects of anti-M2 mAChR antibodies on BRET involve the recognition of the common allosteric site at the II-ECL of M2 mAChR.
Role of antibody valency on BRET enhancing activity
Unlike the undigested ChD IgG fraction, its derived Fab fragment was unable to induce a significant increase in the BRET signal (Fig. 6). In fact, the BRET levels induced by ChD Fab were similar to those obtained in the presence of the Fab fragment derived from control IgG. However, the addition of goat anti-human Fab IgG rescued the ability of ChD Fab, but not control Fab, to enhance BRET. Simultaneous addition of isotype-control goat IgG together with either ChD or control Fab fragments did not lead to a significant recovery of the BRET signal. Taken together, these results suggest that the enhancement of M2 receptor–receptor interaction induced by anti-M2 mAChR antibodies occurs through cross-linking by bivalent antibodies.
Given that BRET is a consequence of protein–protein interaction, and that RLuc and YFP do not interact with each other when expressed as non-fusion proteins, a significant BRET signal between M2-RLuc and M2-YFP (basal BRET ratio) has been interpreted previously as constitutive M2 mAChR dimerization . In the present study, a significant increase in the BRET ratio over the basal value was detected in the presence of the IgG fraction from ChD patients, suggesting that ChD antibodies interact with adjacent receptors, and subsequently enhance M2 receptor–receptor interaction. The observed effect appears to be antibody- and receptor-specific. In fact, serum IgG from control subjects induced a minimum BRET signal, similar to basal BRET values. ChD IgG did not promote an increase in energy transfer between fusion proteins derived from a transmembrane receptor different from the M2 mAChR. The fact that constitutive M3 receptor–receptor interaction was not modified by ChD IgG antibodies was not surprising, as none of the ChD sera involved in this study showed positive immunoreactivity against the II-ECL of M3 mAChR  by ELISA (data not shown), in agreement with our previous report . In addition, exposure of cells co-expressing M2-RLuc and M3-YFP or their reverse combination to ChD IgG did not result in BRET enhancement. These results suggest that, even if ChD IgG antibodies promote an increase in the proximity between two M2 receptors involved in preformed M2–M3 heterodimers, such an arrangement does not favour M2–M3 receptor–receptor interactions.
The BRET signal induced by ChD IgG on the M2-RLuc/M2-YFP cell system did not result simply from the ability of this antibody fraction to bind to or activate the M2 mAChR in the manner of conventional muscarinic ligands. In fact, both orthosteric and allosteric muscarinic ligands failed to mimic the effect of anti-M2 mAChR antibodies on our BRET system (Figs 3 and 5).
It could be argued that these antibodies promote a particular active conformation of the M2 receptor – different from that induced by conventional muscarinic agonists – which could favour the interaction between transmembrane domains from adjacent receptors. However, addition of 10 µm atropine, which has been shown to block activation of M2 mAChR by ChD antibodies [1–3,9–11], could not prevent the enhancing effect of ChD IgG on BRET in cells co-expressing M2-RLuc and M2-YFP, thus suggesting that this effect does not occur as a consequence of receptor activation.
Because ChD IgG antibodies can regulate the expression and function of M2 mAChR by inducing receptor desensitization and sequestration , it could still be conceived that BRET enhancement is promoted by receptor endocytosis. First, pre-treatment of cells with atropine, which is supposed to block agonist-mediated M2 mAChR endocytosis, did not impair the effect of ChD IgG on BRET. Secondly, ChD IgG also promoted BRET enhancement in membranes obtained from cells co-expressing M2-RLuc and M2-YFP, which indicates that the observed effect takes place at the membrane level. Therefore, the hypothesis that the effect of ChD IgG on BRET results from the recruitment of clustered receptors into endocytic vesicles seems unlikely.
In this study, two main differential properties between conventional agonists and agonist-like anti-G protein-coupled receptor (GPCR) antibodies were analysed: binding site on the receptor molecule and valency of ligand. While pharmacological agonists are monovalent and interact with receptor transmembrane residues, agonist-like antibodies are bivalent molecules that recognize extracellular receptor domains. We found that monospecific fractions of ChD IgG antibodies to the II-ECL (anti-pM2 ChD IgG) of human M2 AChR can promote an increase in BRET to the same extent as the total serum IgG from the same patients. Moreover, removal of anti-II-ECL antibodies from the whole ChD IgG fraction generated a non-anti-peptide fraction (non-anti-pM2 ChD IgG), which failed to modulate M2 receptor–receptor interaction. In addition, muscarinic allosteric modulator gallamine inhibited the ChD IgG-mediated increase in BRET under ionic strength conditions that favour allosteric interactions. Taken together, these findings suggest that the enhancement of M2 receptor–receptor interaction by serum ChD IgG antibodies is mediated by the recognition of the common allosteric site at the receptor's II-ECL. This conclusion is supported by the fact that muscarinic ligands interacting with the orthosteric binding site of the M2 receptor, such as carbachol and atropine, could not modify the effect of ChD IgG on BRET (Supplementary Fig. S1 and Fig. 5).
With regard to the role of the valency of ChD IgG antibodies on the modulation of M2 receptor–receptor interaction, we conclude that this effect depends on the integrity of the antibody molecules. Moreover, the ability of anti-Fab antibodies to restore BRET to a similar extent as the complete IgG antibody suggests that bivalent anti-M2 mAChR IgG antibodies can bridge adjacent M2 fusion proteins, thus bringing them into close proximity.
In a previous report using the same BRET methodology as we used in the present study, we provided evidence suggesting that the receptor population in HEK 293 cells only expressing the M2 subtype is composed predominantly of constitutive homodimers (78%) . More recently, FRET-based studies were used to estimate the size of oligomers formed by the M2 mAChR, and concluded that this receptor subtype is most probably a tetramer . In view of these findings, our data suggest that the enhancement in BRET promoted by ChD IgG is more probably a consequence of the clustering of constitutive preformed dimers or higher-order oligomers than the result of cross-linking of monomeric receptors. In fact, the relatively modest increase in BRET (20–25%) induced by ChD IgG antibodies supports the previous interpretation and also suggests that these antibodies could cross-link adjacent receptors involved in preformed dimers (or oligomers), thereby stabilizing pre-established receptor–receptor interactions.
Based on previous studies and the present results, we cannot yet define the pharmacological implications of the effect of ChD antibodies on M2 mAChR receptor–receptor interaction. The basic role of homotropic M2 receptor–receptor interaction in muscarinic receptor pharmacology still remains to be elucidated. However, previous data have provided some insight that deserves further discussion. Elies et al. showed that a monoclonal antibody against the II-ECL of human M2 mAChR, but not its derived Fab fragment, promoted a negative inotropic effect on rat cardiomyocytes through the activation of M2 mAChR . Moreover, the agonist-like activity of this antibody was restored by cross-linking the monovalent fragments with anti-mouse IgG. Because bivalent ChD antibodies can both enhance M2 receptor–receptor interaction and activate the receptor, we propose that such enhanced interaction could contribute to stabilize the active conformation.
Previous studies have provided evidence supporting the role of anti-M2 mAChR antibodies in ChD pathophysiology. Muscarinic agonist-like activity of ChD IgG on the oesophageal smooth muscle was proposed to be involved in the predominantly excitatory unbalance characteristic of chagasic achalasia . In addition, long-term exposure of M2 mAChR from both myocardium [1,3,6,9–13,32] and colonic smooth muscle  to anti-M2 mAChR antibodies is believed to have a causative role in parasympathetic dysfunction (dysautonomia) [1–3,33] and megacolon , respectively, probably via receptor desensitization and sequestration . The present findings, together with those from Elies et al. , suggest that the enhanced M2 receptor–receptor interaction induced by bivalent anti-M2 mAChR IgG antibodies could favour M2 mAChR activation, and consequently trigger the extensively described agonist-like effects that result ultimately in achalasia, dysautonomia and megacolon.
In conclusion, our data demonstrate that the serum IgG fraction from ChD patients can enhance M2 receptor–receptor interaction, and suggest that this effect occurs as a result of receptor cross-linking by bivalent antibodies directed against the receptor's II-ECL. The present study provides a novel insight into the pathophysiological mechanism of anti-autonomic receptor antibodies. In addition, it proposes a sensitive methodology to detect anti-autonomic receptor antibodies in patients suffering from ChD and other pathologies involving such antibodies.
We are grateful to Dr Neil M. Nathanson, University of Washington, Seattle, USA for generously providing the mAChR-derived constructs used throughout the present study. We thank Ms María M. Goin for English editing of the manuscript. This work was funded by the National Scientific and Technical Research Council (CONICET) (PIP grants no. 6480 and 03238 to J. C. G.) and the National Agency of Sciences and Technology (ANPCyT) (PICT grant no. 32404 to C. I. W.) from Argentina. S. P. B. is supported by a CONICET fellowship. C. I. W. and J. C. G. are established researchers from CONICET.
None of the authors has any conflict of interests with the subject matter or materials discussed in this manuscript.